ABEO Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 107957 min ago

@ $6.00

Ausgestellt: 14 Feb 2024 @ 20:22

Rendite: -42.25%

Vorheriges Signal: Feb 14 - 19:08

Vorheriges Signal: Verkaufen

Rendite: -5.73 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 20:40):

Stats
Tagesvolumen	1.79M
Durchschnittsvolumen	527 064
Marktkapitalisierung	94.79M
EPS	$0 ( 2024-04-03 )
Nächstes Ertragsdatum	( $-0.470 ) 2024-05-09
Last Dividend	$3 706.25 ( 2000-03-31 )
Next Dividend	$0 ( N/A )
P/E	-1.370
ATR14	$0.0170 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Seshadri Vishwas	Buy	10 000	Common Stock
2024-04-26	Charles Faith L.	Buy	7 550	Common Stock
2024-04-25	O'malley Brendan M.	Buy	8 600	Common stock
2024-04-25	Vazzano Joseph Walter	Buy	5 608	Common stock
2024-03-15	Vazzano Joseph Walter	Sell	703	Common stock

INSIDER POWER
82.71
Last 95 transactions
Buy: 4 778 989 \| Sell: 610 127

Volumen Korrelation

Lang: -0.38 (neutral)

Kurz: -0.85 (strong negative)

Signal:(44.27) Neutral

Abeona Therapeutics Inc Korrelation

10 Am meisten positiv korreliert
NVDA	0.94
COOL	0.939
BOTZ	0.938
OPRA	0.935
SVAC	0.932
AVGO	0.924
SMCI	0.923
ADVM	0.923
DFH	0.922
TQQQ	0.921

10 Am meisten negativ korreliert
AMRB	-0.953
LWAC	-0.916
NETE	-0.915
SOPA	-0.913
ONCR	-0.909
PHCF	-0.907
SRAC	-0.9
PRDO	-0.89
QTEK	-0.888
AGFS	-0.887

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Abeona Therapeutics Inc Korrelation - Währung/Rohstoff

-0.57
( weak negative )

-0.55
( weak negative )

0.00
( neutral )

-0.71
( moderate negative )

0.71
( moderate )

0.61
( weak )

Abeona Therapeutics Inc Finanzdaten

Annual	2023
Umsatz:	$3.50M
Bruttogewinn:	$302 000 (8.63 %)
EPS:	$-2.53

FY	2023
Umsatz:	$3.50M
Bruttogewinn:	$302 000 (8.63 %)
EPS:	$-2.53

FY	2022
Umsatz:	$1.41M
Bruttogewinn:	$964 000 (68.18 %)
EPS:	$-4.05

FY	2021
Umsatz:	$3.00M
Bruttogewinn:	$3.00M (100.00 %)
EPS:	$-21.57

Financial Reports:

No articles found.

Abeona Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Abeona Therapeutics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$3 706.25	2000-03-31
Last Dividend	$3 706.25	2000-03-31
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$3 706.25	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2000	$3.00	0.03%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-15.48	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.847	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-3.34	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.10	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.103	1.500	4.98	7.47	[0.2 - 2]
debtRatioTTM	0.0844	-1.500	8.59	-10.00	[0 - 0.6]
interestCoverageTTM	-115.31	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.448	2.00	-0.483	-0.965	[0 - 30]
freeCashFlowPerShareTTM	-1.461	2.00	-0.731	-1.461	[0 - 20]
debtEquityRatioTTM	0.364	-1.500	8.54	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0863	1.000	-1.895	-1.895	[0.2 - 0.8]
operatingProfitMarginTTM	-13.77	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-6.85	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0547	0.800	-2.97	-2.38	[0.5 - 2]
Total Score				-2.42

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.537	1.000	-0.256	0	[1 - 100]
returnOnEquityTTM	-3.34	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.461	2.00	-0.487	-1.461	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.448	2.00	-0.483	-0.965	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0712	1.500	-2.86	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-10.57	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.65

Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.